CAR-T Cell Therapy
19
11
13
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 19 trials
5%
1 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (19)
Nutrition OUtReach In Systems of Healthcare
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS
Anti CD19 CAR-T Combined With BTKi to Treat Newly Diagnosed High-risk CLL/SLL
Pre-emptive Anakinra for Cytokine Event Reduction
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cell Therapy in Patients With MDR-SRNS
Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Refractory AAV
CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers
Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients
CAR T-CELL Therapy Educational Video Trial